Guardant Health
JP Morgan Healthcare Conference Day 1: Qiagen, Adaptive Bio, Guardant Health, Natera, Sema4
Highlights of the first day included Qiagen's strategy in the face of the COVID-19 pandemic and Adaptive Bio's development of its two major businesses.
HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders
Premium
New data from a Japanese Phase II study have solidified a path forward for pertuzumab plus trastuzumab in HER2-positive colorectal cancer patients.
In Brief This Week: Guardant Health, Scipher Medicine, Centogene, Thermo Fisher, Biofortuna
News items for the in vitro diagnostics industry for the week of Nov. 1, 2021.
Guardant Health Q3 Revenues Up 27 Percent
The company's recorded record revenue for the quarter of $92.6 million, driven by increases in its precision oncology clinical testing business.
360Dx Index Maintains Steady Ascent, Increasing 3 Percent in August
Of the 29 companies in the index, 18 saw increases in their stock prices, while 11 saw declines.
Aug 5, 2021
Guardant Health Q2 Revenues Grow 39 Percent
Jun 22, 2021
May 6, 2021
Guardant Health Q1 Revenues up 17 Percent
Feb 24, 2021
Guardant Health Q4 Revenues Up 25 Percent
Feb 5, 2021